Log in to save to my catalogue

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from P...

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from P...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3101793874

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial

About this item

Full title

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial

Publisher

Netherlands: Elsevier Ltd

Journal title

Vaccine, 2024-11, Vol.42 (25), p.126275-126275, Article 126275

Language

English

Formats

Publication information

Publisher

Netherlands: Elsevier Ltd

More information

Scope and Contents

Contents

AbstractBackgroundBBV152 (Covaxin™) is a whole-virion inactivated SARS-CoV-2 vaccine mixed with an immune adjuvant. We aimed to compare immune responses after booster vaccination with heterologous BBV152 versus homologous mRNA vaccine. MethodsWe conducted a randomized, participant-blinded, controlled trial. Fifty mRNA-vaccinated participants were e...

Alternative Titles

Full title

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_3101793874

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3101793874

Other Identifiers

ISSN

0264-410X,1873-2518

E-ISSN

1873-2518

DOI

10.1016/j.vaccine.2024.126275

How to access this item